BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 17390239)

  • 21. Active immunotherapy of cancer for minimal residual disease: new trends and new materials.
    Mathé G; Florentin I; Olsson L; Kiger N; Bruley-Rosset M; Orbach-Arbouys S; Schulz JI
    Prog Exp Tumor Res; 1980; 25():242-74. PubMed ID: 6986635
    [No Abstract]   [Full Text] [Related]  

  • 22. [New method in the therapy of cancer. Interview granted to Minerva Medica by Prof. Augusto Pederzini].
    Carafa M
    Minerva Med; 1973 Apr; 64(25):3-6. PubMed ID: 4709744
    [No Abstract]   [Full Text] [Related]  

  • 23. Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer.
    Ramakrishnan R; Gabrilovich DI
    Cancer Immunol Immunother; 2011 Mar; 60(3):419-23. PubMed ID: 20976448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Immunostimulation in the treatment of malignant diseases].
    Havemann K
    Internist (Berl); 1975 Oct; 16(10):471-81. PubMed ID: 1107253
    [No Abstract]   [Full Text] [Related]  

  • 25. Immunotherapy in non-renal carcinomas.
    Keilholz U
    Urologe A; 2004 Sep; 43 Suppl 3():S138-40. PubMed ID: 15148577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.
    Obeid J; Hu Y; Slingluff CL
    Semin Oncol; 2015 Aug; 42(4):549-61. PubMed ID: 26320060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic vaccines for cancer: an overview of clinical trials.
    Melero I; Gaudernack G; Gerritsen W; Huber C; Parmiani G; Scholl S; Thatcher N; Wagstaff J; Zielinski C; Faulkner I; Mellstedt H
    Nat Rev Clin Oncol; 2014 Sep; 11(9):509-24. PubMed ID: 25001465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccines: an innovative approach to treating cancer.
    Pazdur MP; Jones JL
    J Infus Nurs; 2007; 30(3):173-8. PubMed ID: 17505219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted cancer immunotherapy.
    Zigler M; Shir A; Levitzki A
    Curr Opin Pharmacol; 2013 Aug; 13(4):504-10. PubMed ID: 23648271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer vaccines.
    Butterfield LH
    BMJ; 2015 Apr; 350():h988. PubMed ID: 25904595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer vaccines. Any future?
    Myc LA; Gamian A; Myc A
    Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):249-59. PubMed ID: 21644030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toll-like receptor 4 activation in cancer progression and therapy.
    Oblak A; Jerala R
    Clin Dev Immunol; 2011; 2011():609579. PubMed ID: 22110526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of mycobacterial adjuvant-based agents for immunotherapy of cancer.
    Grange JM; Bottasso O; Stanford CA; Stanford JL
    Vaccine; 2008 Sep; 26(39):4984-90. PubMed ID: 18625281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent progress in supramolecular peptide assemblies as virus mimics for cancer immunotherapy.
    Cai Y; Ran W; Zhai Y; Wang J; Zheng C; Li Y; Zhang P
    Biomater Sci; 2020 Feb; 8(4):1045-1057. PubMed ID: 31637384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of adjuvants for immunotherapy.
    Circelli L; Tornesello M; Buonaguro FM; Buonaguro L
    Hum Vaccin Immunother; 2017 Aug; 13(8):1774-1777. PubMed ID: 28604160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The fourth modality: immunotherapy for head and neck cancer hits pay dirt.
    Bell RB
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Jun; 121(6):575-7. PubMed ID: 27181440
    [No Abstract]   [Full Text] [Related]  

  • 37. CCL5 as an adjuvant for cancer immunotherapy.
    Lapteva N; Huang XF
    Expert Opin Biol Ther; 2010 May; 10(5):725-33. PubMed ID: 20233026
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical trials exploring the benefit of immunotherapy and radiation in cancer treatment: A review of the past and a look into the future.
    Naghavi AO; Johnstone PA; Kim S
    Curr Probl Cancer; 2016; 40(1):38-67. PubMed ID: 26656977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lessons learned from cancer vaccine trials and target antigen choice.
    Butterfield LH
    Cancer Immunol Immunother; 2016 Jul; 65(7):805-12. PubMed ID: 26842127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Harnessing dendritic cells in cancer.
    Apetoh L; Locher C; Ghiringhelli F; Kroemer G; Zitvogel L
    Semin Immunol; 2011 Feb; 23(1):42-9. PubMed ID: 21295491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.